Herceptin was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-positive tumour cells, blocking them from receiving growth signals and flagging them for destruction by the immune system.
In the United States, Europe and many other countries, Herceptin is approved in combination with chemotherapy for the adjuvant (post-surgery) treatment of HER2-positive early breast cancer, first-line treatment of advanced HER2-positive breast cancer and first-line treatment of advanced HER2-positive gastric cancer. In Europe and other countries, it is also approved in combination with chemotherapy for the neoadjuvant (pre-surgery) treatment of HER2-positive early breast cancer.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.